Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
A 2024 study published in JAMA Ophthalmology found that patients prescribed semaglutide had a higher observed risk of NAION compared with patients using non-GLP-1 medications for diabetes or weight loss
Current BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
Slows gastric emptying
PlexusDx recognizes this emerging body of evidence while maintaining realistic expectations about current approval status
US$ 25.62
US$ 20.14
US$ 29.54
US$ 24.35
US$ 22.86
US$ 20.17
US$ 25.88
US$ 28.58
